Invasive lobular carcinoma of the breast: lines of therapy

Cancer page →

1 standard-of-care settings across 1 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	HR-positive
Other settings	1

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
HR-positive	All stages	Treated as HR-positive breast cancer: surgery planned with MRI, endocrine therapy, CDK4/6 inhibitors in advanced disease; sentinel node biopsy as in ductal disease.	HR-positive / HER2-negative breast cancerEndocrine therapy (SERMs, AIs, SERDs)CDK4/6 inhibitorsTamoxifenLetrozole (and other aromatase inhibitors)Mastectomy		91

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.